ALFA FinderNSE filing, NSE: EMCURE. Summary written from the filing by ALFA Finder's alert engine.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,212.80
- Market cap
- ₹41,979 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 38.4×Sector 43.0×
- Promoter holding
- 77.82%-0.01% QoQ
- FII holding
- 4.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹2,820 Cr (+24%) and PAT ₹325 Cr (+29%) were strong. FY27 revenue growth guidance raised to above 20%. Net debt rose ₹263 Cr on acquisition payouts. FY28 guidance withheld.
- Call
- Guides 20% growth
Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Q2FY27 revenue INR 28,205 Mn (+24.3% YoY), EBITDA INR 5,748 Mn (20.4% margin, +103 bps), PAT INR 3,251 Mn (+29.3%). International-led growth; net debt rose on acquisition payments.
Emcure Pharmaceuticals Q2 FY27 Results: Net Profit ₹325.1 Cr, Up 29.3% YoY
Emcure Pharmaceuticals Ltd reported revenue from operations of ₹2,820 Cr (+24.3% YoY) and net profit of ₹325.1 Cr (+29.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹325.1 Cr · +29.3% YoY
Emcure Pharmaceuticals Other Announcement
Emcure Pharmaceuticals submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance disclosure under SEBI.
Emcure Pharmaceuticals Board Meeting Date
Emcure Pharmaceuticals will hold a board meeting on November 03, 2026, to consider and approve the company's standalone and consolidated financial results for the quarter.
Emcure Pharmaceuticals Acquisition
Emcure Pharmaceuticals approved the merger of its wholly-owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, into itself. The internal restructuring involves no cash consideration or share issuance.
Other business update announcements
All →Italian Edibles Business Update
Italian Edibles revised its project timeline again, pushing commercial production from January 2027 to April 2027. Construction delays stem from steel prices, supply chain disruption, weather and labour shortages.
- Execution
- Commercial production revised to April 2027 from January 2027
Bajaj Finserv Business Update
Bajaj Finserv disclosed October 2026 monthly premium and new business data for its unlisted insurance subsidiaries. The figures are provisional.
Bajaj Finance Business Update
Bajaj Finance submitted its Half Yearly Report for FY2026-27 covering the six months to 30 September 2026. The report shows 28% consolidated PAT growth to ₹12,447 crore and a planned ₹17,500 crore capital raise.
Cohance Lifesciences Business Update
Cohance Lifesciences disclosed that USFDA issued the Establishment Inspection Report for its Pashamylaram facility, classifying the inspection as Voluntary Action Indicated. The inspection is now concluded.
Religare Enterprises Business Update
Religare Finvest, a material subsidiary, resumed lending after RBI lifted its Corrective Action Plan. It disbursed its first Loan Against Property on 6 November 2026.
Purple Wave Infocom Business Update
Purple Wave signed a 5-year data integration agreement with BPCL for its Hygiair devices. The Rs 10 crore figure is indicative, not firm order value.
- Execution
- 5 years